
Every investigational drug in clinical development produces one document a year that asks a single question: given everything learned this year, is it still reasonable to expose people to this drug in trials? That document is the Development Safety Update Report (DSUR), and the judgment it depends on is usually learned the slow way.
Writing the DSUR is a practical, section-by-section manual for writing ICH E2F Development Safety Update Reports that regulators can trust. It goes beyond what the guideline requires to teach the judgment behind a strong report: deciding what the reporting period actually changed, reading imbalances in blinded data without unblinding, writing an overall safety assessment that interprets rather than repeats, keeping the summary of important risks honest from year to year, and running the process so the report lands inside the 60-day window.
Inside you will find:
Written by Dr. Hafez Selim, MD, PhD, a physician-scientist with long experience in drug and medical device safety, for safety physicians, safety scientists, clinical development leads, medical writers and regulatory affairs professionals in pharma and biotech.
Es wurden noch keine Bewertungen abgegeben. Schreiben Sie die erste Bewertung zu "Writing the DSUR" und helfen Sie damit anderen bei der Kaufentscheidung.